Introduction of Academia-Based Drug Discovery Seeds and Bridging to Global Markets
First written in FY2023. 6 of 8 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2027-H1.
0 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「The Company also continued examining expanded indications for TMS-008 and began collaborative research with Kyushu University and Tohoku University.」
The Company continued introducing and evaluating external seeds, began collaborative research with Kyushu University and Tohoku University and advanced evaluation of a new Hokkaido University seed. - FY2025RestatedAnnual report
「The Company’s growth strategy is to actively introduce drug-discovery seeds from academia, primarily in Japan, expand its pipeline, pursue expansion into global pharmaceutical markets, and achieve future growth by bridging scientific breakthroughs in Japanese academia with the global pharmaceutical industry.」
The Company reaffirmed its growth strategy of building on its clinical-stage pipeline, introducing Japanese academic drug-discovery seeds and expanding into global markets. - FY2025-H1AdvancedAnnual report
「During the interim accounting period, the Company worked toward entering clinical trials by advancing the necessary nonclinical studies, including GLP studies, developing GMP-level formulations for the Phase I trial and beginning to formulate the clinical trial plan.」
After adding TMS-010 to its pipeline, the Company began GLP and other nonclinical studies, GMP formulation development and preparation of the clinical trial plan. - FY2025-Q1AdvancedAnnual report
「For the seed evaluated under an option agreement signed with Hokkaido University in July 2022, the Company entered into a license agreement with the university on 3 July 2024 after the end of the first quarter and acquired an exclusive worldwide development and commercialization license as TMS-010, a spinal cord injury drug candidate.」
Evaluation of a Hokkaido University seed culminated in the acquisition of an exclusive worldwide license for TMS-010 on 3 July 2024. - FY2024-Q3AdvancedAnnual report
「The drug candidate covered by the option agreement with Hokkaido University signed on 8 May 2023 entered its second phase after completing the first phase of the exclusive evaluation period. The Company also entered into a three-party joint research agreement including Kanazawa University.」
Evaluation of the Hokkaido University candidate advanced to Phase 2, and a three-party joint research agreement including Kanazawa University was signed. - FY2024-Q2AdvancedAnnual report
「For external programs, the Company continued searching for and evaluating early-stage programs at academic and other research institutions and drug-discovery companies. On 8 May 2023, it entered into an option agreement with Hokkaido University for the exclusive evaluation and licensing of a drug candidate and began evaluating that candidate. It completed evaluation of a program for which it had entered into an option agreement with the university in July 2022 and is discussing the next steps based on the results.」
Evaluation of a Hokkaido University candidate began, while another program completed evaluation and advanced to discussions on the next step. - FY2024-Q1AdvancedAnnual report
「For external programs, the Company continued searching for and evaluating programs in the early research and development stages at academic and other research institutions and drug-discovery companies. On 8 May 2023, it entered into an option agreement with Hokkaido University for the exclusive evaluation and licensing of a drug candidate.」
The Company continued searching for and evaluating early-stage academic programs and advanced to evaluating a specific candidate under an exclusive evaluation and licensing option agreement with Hokkaido University. - FY2023First statedAnnual report
「The Company’s growth strategy is to actively introduce drug-discovery seeds from academia, primarily in Japan, expand its pipeline, pursue expansion into global pharmaceutical markets, and achieve future growth by bridging scientific breakthroughs in Japanese academia with the global pharmaceutical industry.」
The Company identifies the introduction and development of Japanese academic drug-discovery seeds and their connection to global markets as a core growth strategy.